TARA-002 demonstrates high complete response rates in BCG-naïve NMIBC patients, with 72% achieving CR and 50% maintaining it at 12 months. The treatment involves six weekly bladder instillations, ...
PALO ALTO, Calif.--(BUSINESS WIRE)--Valar Labs, the developer of computational histology AI tests for predicting response to cancer therapies, announced new data today which is being presented on ...
Protara’s lead candidate, TARA-002, has demonstrated durable complete response (CR) rates in a single-arm Phase II trial in Bacillus Calmette-Guérin (BCG)-naïve non-muscle invasive bladder cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback